PDX model details
PDX ID | 167.2M Cx |
---|---|
Host Strain(and Source) | NSG Source: Monash University |
Host Strain Immune system Humanized | NO |
Host Type | Castrate |
Graft Site | Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
29 (12*) |
Average PDX Generation Time (days +/- SEM) | 94 ± 7 |
Tumor preparation | Tumor solid |
Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
Passage QA performed | Routine QA every 2-3 passages |
Associated meta data | |
PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
Pubmed ID | 34413304; 33620092 |
Markers | 167.2M Cx |
---|---|
AR | Y |
PSA | Y |
PSMA | Y |
NE | N |
ERG | N |
This table displays curated CNVs
PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
---|---|---|---|---|---|---|---|
167.2M Cx | AKT3 | 0.521305 | 2.87051 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | XPO1 | 0.511275 | 2.85062 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | SPEN | 0.55372 | 2.93573 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | PIK3CB | 0.781321 | 3.43741 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | PIK3CA | 0.781321 | 3.43741 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | IGF2R | 0.559565 | 2.94765 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | CCND1 | 1.10509 | 4.30225 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | ARID2 | 0.593568 | 3.01795 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | STAB2 | 0.584307 | 2.99864 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | NCOR2 | 0.605661 | 3.04335 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | FOXA1 | 1.16298 | 4.47839 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | AR | 2.95049 | 7.73012 | gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | APC | -1.5106 | 0.70193 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | ZNRF3 | -1.47735 | 0.718296 | loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
167.2M Cx | PTEN | -10.6738 | 0.00122432 | homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
Sample Number | 167.2M |
---|---|
Sample Site | Spine |
Sample source | Surgery |
Pathology Tumor Diagnosis | Adenocarcinoma |
Gleason Score | 9 |
Primary Gleason Score | 4 |
Secondary Gleason Score | 5 |
Tertiary Gleason Score | None |
ISUP Grade Group | |
Tumor Grade | |
D'Amico Risk Classification | |
Tumor Volume (in cc) | 0.0 |
Treatment Prior to Specimen Collection | ADT, docetaxel |
Patient Information
Patient Number | 167 |
---|---|
Sex | Male |
Diagnosis | Prostate Cancer |
PSA at diagnosis (ng/mL) | 5.2 |
Consent to share data | |
Patient Tumor Collection (Current Model) | |
---|---|
Tumour sample ID | 167.2M |
Patient Age (binned in 5 year age groups) | 55-59 |
This table displays curated sequence variants
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
PDX ID | Gene Symbol | Depth | ALT_FREQ | Consequence | Exon | GnomAD_AF | CADD_PHRED | Clinvar_clnsig | Platform | Experiments Name | Reference | Library Type | Instrument Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
167.2M Cx | TP53 | 211 | 1.0 | missense_variant | '7/11 | . | 32 | Uncertain_significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
167.2M Cx | APC | 85 | 0.88 | frameshift_variant | '16/16 | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
167.2M Cx | PRLR | 532 | 0.54 | missense_variant | '10/10 | 0.0008899 | 23.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
167.2M Cx | DCLK3 | 372 | 0.41 | missense_variant | '4/5 | . | 25.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
This table displays drug response data
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
---|---|---|---|---|---|---|---|
167.2M Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | No response |
167.2M Cx | Carboplatin | 50 | qwk | NA | NA | NA | Response |
167.2M Cx | Talazoparib | 0.33 | qd | NA | NA | NA | No response |